Mepolizumab is efficacious in COPD patients with varying levels of airflow obstruction: Pooled Phase III trial results - Amsterdam 2025

Recent advances in the management and treatment of airways disease

Chair(s): Gert-Jan Braunstahl, Astrid Aardenburg - van Huisstede

Session type: Poster session

Mepolizumab is efficacious in COPD patients with varying levels of airflow obstruction: Pooled Phase III trial results

David M. G. Halpin

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Impact of adherence to sublingual grass pollen allergen immunotherapy on allergy medication use in patients with allergic rhinoconjunctivitis

Morten Borg

Poster

Abstract

Online recorded patient reported outcome measures in the Severe Heterogeneous Asthma Research Collaboration Patient-centered (SHARP) registry could provide information for early assessment of response to biologics in patients with severe asthma

Valentyna Yasinska

Poster

Abstract

Agonism of TRPM8 Alleviates Cough Responses to Inhaled Allyl Isothiocyanate (AITC) in Patients with Allergic Rhinitis

Yang Yang

Poster

Abstract

Hyperosmolar Therapy with Xylitol vs Placebo in the Treatment of Allergic Rhinitis: Results of a Double-Blind Placebo-Controlled Study

Artemii Bogomolov

Poster

Abstract

Mepolizumab reduces exacerbations and improves quality of life in COPD irrespective of severe exacerbation history: Pooled Phase III trial results

Alberto Papi

Poster

Abstract

Hormone replacement therapy and late-onset asthma: A 15-year cohort study of 1.7 million menopausal women

Fatima Almaghrabi

Poster

Abstract

Mepolizumab is efficacious in COPD patients with varying levels of airflow obstruction: Pooled Phase III trial results

David M. G. Halpin

Poster

Abstract

Clinical Remission in severe asthma with biologic treatment in a portuguese Severe Asthma Multidisciplinary Unit (SAMU)

Ana Patrícia Soares Trindade

Poster

Abstract

Phase 1 study of TQC2731 targeting thymic stromal lymphopoietin in Chinese healthy adults and asthma patients

Li Mei

Poster

Abstract

Reduction of Inhaled Corticosteroids After Biologic Therapy Initiation in Severe Asthma: Prevalence and Impact in the German Severe Asthma Registry

Slagjana Stoshikj

Poster

Abstract

Efficacy of hypertonic saline nasal irrigation in allergic rhinitis: a systematic review and meta-analysis

Nishtha Singh

Poster

Abstract

Efficacy and safety of add-on dupilumab vs inhaled corticosteroid (ICS) dose escalation in patients with asthma uncontrolled on medium-dose ICS/long-acting ?2-agonist (LABA) AIM4: Next Step study

Mena Soliman

Poster

Abstract

Clinical Remission in Patients with Asthma treated with Triple Inhalation Therapy: Post-hoc Evaluation of TRIMARAN and TRIGGER RCTs

Ulrica Scaffidi Argentina

Poster

Abstract

Baseline characteristics of patients with asthma initiating dupilumab in the real-world REVEAL registry

Mona Al-ahmad

Poster

Abstract

Real-world outcomes after 2 years of dupilumab therapy for severe asthma: the ProVENT study

Henrik Watz

Poster

Abstract

The Combined Impact of Omalizumab and Allergen Immunotherapy (AIT) in Severe Asthma.

Laura Lopes

Poster

Abstract

Updates in the clinical practice of SEVERE ASTHMA Latin American Thoracic Society-ALAT

Ana Maria Stok

Poster

Abstract

Psychometric validation of the Asthma Daytime/Nighttime Symptom Diary (ADSD/ANSD) in a phase 2 trial with adults with moderate-to-severe uncontrolled asthma

Jane Wells

Poster

Abstract

Should Omalizumab Therapy Be Discontinued?

Ezgi Akkus

Abstract

Indirect treatment comparison (ITC) of mepolizumab and dupilumab in treating COPD

Jean Bourbeau

Poster

Abstract

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}